KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,985 ILa | +0.05% |
|
-0.05% | -10.87% |
| Mar. 06 | Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024 | |
| Mar. 06 | Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
ETFs positioned on Kamada Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.87% | 306M | |
| -4.24% | 86.85B | |
| +2.76% | 40.16B | |
| -16.48% | 31.28B | |
| +57.86% | 25.27B | |
| -13.58% | 15.33B | |
| -9.12% | 11.96B | |
| -42.56% | 11.61B | |
| +6.89% | 8.83B | |
| -10.53% | 7.94B |
- Stock Market
- Equities
- KMDA Stock
- Funds and ETFs Kamada Ltd.
